Literature DB >> 10690890

Relationship between disease duration and predominant orbital T cell subset in Graves' ophthalmopathy.

J P Aniszewski1, R W Valyasevi, R S Bahn.   

Abstract

We sought to determine whether the predominant orbital T helper (T(H)) cell subset in orbital T cell clones established from patients with Graves' ophthalmopathy (GO) might be related to disease duration. A total of 117 clones were established from orbital adipose/connective tissues of 6 GO patients, and cytokine production was measured in 57 CD3+CD4+ clones. T(H)1-type clones were predominant in cultures from patients with recent onset (<2 yr) Graves' hyperthyroidism (n = 44; TH1/TH0/TH2 = 57/29/14%) or GO (n = 53 clones; TH1/TH0/TH2 = 47/30/23%). In contrast, TH2-type clones predominated in cultures from patients with more remote onset (>2 yr) hyperthyroidism (n = 13; TH1/TH0/TH2 = 0/31/69%; P < 0.005) or GO (n = 4; TH1/TH0/TH2 = 0/25/75%; P = 0.05). In addition, we established T cell clones from 1 TH1-dominant patient with recent-onset thyroid and eye disease using either IL-2 (12.5 ng/mL) alone or IL-2 plus IL-4 (5 ng/mL) and found no shift toward recovery of TH2-type clones in the latter. In conclusion, although the CD3+CD4+ clones characterized were not necessarily tissue antigen specific, our findings suggest that cell-mediated (TH1-type) immune reactions may predominate in the orbit in early GO, whereas humoral immunity (TH2-type) might play the greater role in later stages of the disease.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10690890     DOI: 10.1210/jcem.85.2.6333

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  32 in total

Review 1.  Unlocking the immunological mechanisms of orbital inflammation in thyroid eye disease.

Authors:  M Ludgate; G Baker
Journal:  Clin Exp Immunol       Date:  2002-02       Impact factor: 4.330

Review 2.  New understanding of the role of cytokines in the pathogenesis of Graves' ophthalmopathy.

Authors:  R A Ajjan; A P Weetman
Journal:  J Endocrinol Invest       Date:  2004-03       Impact factor: 4.256

3.  Thyroid associated ophthalmopathy: evidence for CD4(+) gammadelta T cells; de novo differentiation of RFD7(+) macrophages, but not of RFD1(+) dendritic cells; and loss of gammadelta and alphabeta T cell receptor expression.

Authors:  A K Eckstein; B Quadbeck; S Tews; K Mann; C Krüger; C H Mohr; K-P Steuhl; J Esser; R K Gieseler
Journal:  Br J Ophthalmol       Date:  2004-06       Impact factor: 4.638

Review 4.  Current concepts in the molecular pathogenesis of thyroid-associated ophthalmopathy.

Authors:  Yao Wang; Terry J Smith
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-03-20       Impact factor: 4.799

Review 5.  Graves' ophthalmopathy.

Authors:  Rebecca S Bahn
Journal:  N Engl J Med       Date:  2010-02-25       Impact factor: 91.245

6.  [Calculation of orbital fat volumes for determining treatment timing for thyroid- associated ophthalmopathy].

Authors:  Wei Jiang; Qiu-Yue Cai; Zhang-Fang Li; Zhi-Yi Chen; Yao-Sheng Luo; Shi-di Hu; Jie Shen
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2017-05-20

Review 7.  Differential involvement of orbital fat and extraocular muscles in graves' ophthalmopathy.

Authors:  Wilmar M Wiersinga; Noortje I Regensburg; Maarten P Mourits
Journal:  Eur Thyroid J       Date:  2013-02-26

Review 8.  Role for interferon-gamma inducible chemokines in endocrine autoimmunity: an expanding field.

Authors:  M Rotondi; E Lazzeri; P Romagnani; M Serio
Journal:  J Endocrinol Invest       Date:  2003-02       Impact factor: 4.256

9.  A stimulatory thyrotropin receptor antibody (M22) and thyrotropin increase interleukin-6 expression and secretion in Graves' orbital preadipocyte fibroblasts.

Authors:  Seema Kumar; Reagan Schiefer; Michael J Coenen; Rebecca S Bahn
Journal:  Thyroid       Date:  2010-01       Impact factor: 6.568

10.  Expression of IP-10/CXCL10 and MIG/CXCL9 in the thyroid and increased levels of IP-10/CXCL10 in the serum of patients with recent-onset Graves' disease.

Authors:  Paola Romagnani; Mario Rotondi; Elena Lazzeri; Laura Lasagni; Michela Francalanci; Andrea Buonamano; Stefano Milani; Paolo Vitti; Luca Chiovato; Massimo Tonacchera; Antonio Bellastella; Mario Serio
Journal:  Am J Pathol       Date:  2002-07       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.